BackMaravai LifeSciences Holdings Overview

Maravai LifeSciences Holdings Other Current Liabilities

Maravai LifeSciences Holdings's other current liabilities is $30M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$30.17M
28.64% YoYΔ $-12.11M vs prior year quarter

Peer trimmed avg / median

Loading

Maravai LifeSciences Holdings Other Current Liabilities History

Loading

Maravai LifeSciences Holdings vs. peers: Other Current Liabilities Comparison

Loading

Maravai LifeSciences Holdings Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Maravai LifeSciences Holdings (MRVI) FAQ

Maravai LifeSciences Holdings's other current liabilities stands at $30M as of June 2026. That compares with $42M in the prior-year period — down 28.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Maravai LifeSciences Holdings reported $30M in other current liabilities versus $42M a year earlier — a 28.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $42M in the prior-year period — down 28.6% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Maravai LifeSciences Holdings's other current liabilities evolved across reporting periods, while the comparison chart places MRVI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Maravai LifeSciences Holdings's reading of $30M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.